| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| BRCA1 Protein | 20 | 2023 | 222 | 1.840 |
Why?
|
| Genetic Predisposition to Disease | 39 | 2026 | 2579 | 1.800 |
Why?
|
| BRCA2 Protein | 17 | 2025 | 178 | 1.780 |
Why?
|
| Precision Medicine | 9 | 2021 | 502 | 1.360 |
Why?
|
| Breast Neoplasms | 26 | 2023 | 3285 | 1.350 |
Why?
|
| Ovarian Neoplasms | 15 | 2023 | 828 | 1.330 |
Why?
|
| Genetic Testing | 11 | 2026 | 606 | 1.300 |
Why?
|
| Pharmacogenetics | 7 | 2024 | 473 | 1.220 |
Why?
|
| Mutation | 24 | 2023 | 4428 | 0.920 |
Why?
|
| Genes, BRCA2 | 7 | 2019 | 162 | 0.900 |
Why?
|
| Genes, BRCA1 | 7 | 2019 | 191 | 0.890 |
Why?
|
| Heterozygote | 17 | 2025 | 392 | 0.770 |
Why?
|
| Primary Health Care | 3 | 2021 | 402 | 0.740 |
Why?
|
| Germ-Line Mutation | 9 | 2025 | 402 | 0.740 |
Why?
|
| Genetics, Population | 2 | 2021 | 450 | 0.650 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 72 | 0.630 |
Why?
|
| Polymorphism, Single Nucleotide | 17 | 2022 | 2574 | 0.630 |
Why?
|
| Patients | 1 | 2021 | 104 | 0.620 |
Why?
|
| Genome-Wide Association Study | 12 | 2021 | 1859 | 0.620 |
Why?
|
| Prostatic Neoplasms | 9 | 2022 | 1842 | 0.590 |
Why?
|
| Health Literacy | 1 | 2021 | 92 | 0.590 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2026 | 314 | 0.530 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 220 | 0.520 |
Why?
|
| Multifactorial Inheritance | 4 | 2026 | 236 | 0.470 |
Why?
|
| Genomics | 6 | 2026 | 903 | 0.460 |
Why?
|
| Humans | 76 | 2026 | 98370 | 0.450 |
Why?
|
| Risk Factors | 23 | 2026 | 6273 | 0.430 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2016 | 81 | 0.420 |
Why?
|
| Female | 53 | 2026 | 51761 | 0.410 |
Why?
|
| Risk Assessment | 11 | 2026 | 2599 | 0.380 |
Why?
|
| Adult | 33 | 2026 | 29587 | 0.370 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 479 | 0.370 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 558 | 0.360 |
Why?
|
| Middle Aged | 30 | 2026 | 29532 | 0.360 |
Why?
|
| Pharmacogenomic Testing | 3 | 2018 | 119 | 0.350 |
Why?
|
| Biological Specimen Banks | 4 | 2026 | 82 | 0.330 |
Why?
|
| Neoplasms | 6 | 2025 | 3349 | 0.330 |
Why?
|
| Physicians | 2 | 2021 | 685 | 0.330 |
Why?
|
| Pedigree | 8 | 2025 | 987 | 0.310 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 41 | 0.310 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 70 | 0.310 |
Why?
|
| Alleles | 6 | 2021 | 1163 | 0.300 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 54 | 0.290 |
Why?
|
| Body Height | 2 | 2019 | 109 | 0.280 |
Why?
|
| Mastectomy | 3 | 2016 | 273 | 0.280 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 235 | 0.280 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 353 | 0.280 |
Why?
|
| Male | 30 | 2026 | 47263 | 0.270 |
Why?
|
| Aged | 21 | 2026 | 21844 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2024 | 686 | 0.270 |
Why?
|
| Chromosome Mapping | 3 | 2020 | 1064 | 0.240 |
Why?
|
| Quantitative Trait Loci | 6 | 2021 | 665 | 0.240 |
Why?
|
| Hypertrichosis | 1 | 2025 | 5 | 0.230 |
Why?
|
| Hand Deformities, Congenital | 1 | 2025 | 16 | 0.230 |
Why?
|
| Cryptorchidism | 1 | 2025 | 13 | 0.230 |
Why?
|
| Smad4 Protein | 1 | 2025 | 27 | 0.230 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 336 | 0.230 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2026 | 105 | 0.230 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2025 | 12 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1290 | 0.220 |
Why?
|
| Penetrance | 1 | 2025 | 51 | 0.220 |
Why?
|
| Genetic Counseling | 1 | 2025 | 111 | 0.220 |
Why?
|
| Colorectal Neoplasms | 3 | 2025 | 1110 | 0.220 |
Why?
|
| Body Mass Index | 2 | 2019 | 867 | 0.220 |
Why?
|
| Phenotype | 8 | 2025 | 2667 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 578 | 0.220 |
Why?
|
| Receptors, Estrogen | 3 | 2020 | 430 | 0.220 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2025 | 52 | 0.220 |
Why?
|
| Prostate | 2 | 2022 | 434 | 0.210 |
Why?
|
| Intellectual Disability | 1 | 2025 | 215 | 0.210 |
Why?
|
| Patient Transfer | 1 | 2014 | 112 | 0.190 |
Why?
|
| Community Health Planning | 3 | 2018 | 23 | 0.190 |
Why?
|
| United Kingdom | 4 | 2026 | 212 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1775 | 0.190 |
Why?
|
| Software | 2 | 2020 | 697 | 0.190 |
Why?
|
| DNA Copy Number Variations | 3 | 2022 | 206 | 0.180 |
Why?
|
| Case-Control Studies | 7 | 2020 | 2009 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 7418 | 0.180 |
Why?
|
| Exome | 3 | 2021 | 149 | 0.180 |
Why?
|
| Genes, Dominant | 2 | 2025 | 112 | 0.170 |
Why?
|
| Medical History Taking | 2 | 2025 | 81 | 0.170 |
Why?
|
| Genotype | 7 | 2021 | 1892 | 0.170 |
Why?
|
| Coronary Artery Disease | 1 | 2026 | 391 | 0.170 |
Why?
|
| Inpatients | 1 | 2014 | 367 | 0.170 |
Why?
|
| Genetic Variation | 3 | 2019 | 1454 | 0.170 |
Why?
|
| Mutation, Missense | 2 | 2020 | 309 | 0.160 |
Why?
|
| Heart Arrest | 1 | 2014 | 315 | 0.160 |
Why?
|
| Health Personnel | 2 | 2021 | 257 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 177 | 0.160 |
Why?
|
| Urogenital Abnormalities | 1 | 2020 | 19 | 0.160 |
Why?
|
| Intensive Care Units | 1 | 2014 | 474 | 0.160 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2020 | 69 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2024 | 428 | 0.160 |
Why?
|
| Young Adult | 7 | 2021 | 7568 | 0.160 |
Why?
|
| Thrombosis | 1 | 2023 | 318 | 0.160 |
Why?
|
| Urinary Tract | 1 | 2020 | 34 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2014 | 450 | 0.150 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 2471 | 0.150 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 124 | 0.150 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2019 | 1 | 0.150 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 184 | 0.150 |
Why?
|
| Prospective Studies | 7 | 2023 | 4818 | 0.150 |
Why?
|
| Illinois | 1 | 2021 | 524 | 0.150 |
Why?
|
| Hexokinase | 1 | 2019 | 23 | 0.150 |
Why?
|
| Nipples | 2 | 2016 | 40 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2024 | 3228 | 0.140 |
Why?
|
| Inheritance Patterns | 1 | 2019 | 55 | 0.140 |
Why?
|
| Databases, Genetic | 3 | 2018 | 289 | 0.140 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 589 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2019 | 242 | 0.130 |
Why?
|
| Internationality | 1 | 2018 | 80 | 0.130 |
Why?
|
| Exons | 2 | 2016 | 457 | 0.130 |
Why?
|
| Prognosis | 6 | 2019 | 4126 | 0.130 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 316 | 0.130 |
Why?
|
| Genes, Modifier | 1 | 2017 | 5 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 649 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2020 | 449 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 3032 | 0.130 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 1268 | 0.130 |
Why?
|
| Community Pharmacy Services | 1 | 2016 | 6 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 317 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 568 | 0.120 |
Why?
|
| Point Mutation | 2 | 2016 | 237 | 0.120 |
Why?
|
| Professional Role | 1 | 2016 | 40 | 0.120 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 65 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2016 | 61 | 0.120 |
Why?
|
| Genetic Carrier Screening | 1 | 2016 | 58 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2016 | 64 | 0.120 |
Why?
|
| Adenomatous Polyps | 1 | 2016 | 15 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 79 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2024 | 11043 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2016 | 42 | 0.120 |
Why?
|
| Adolescent | 7 | 2026 | 10140 | 0.120 |
Why?
|
| Codon, Terminator | 1 | 2015 | 20 | 0.120 |
Why?
|
| Breast Neoplasms, Male | 1 | 2016 | 32 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2016 | 44 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 602 | 0.120 |
Why?
|
| Transcriptome | 2 | 2020 | 824 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2017 | 263 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 127 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 923 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2056 | 0.110 |
Why?
|
| Connective Tissue Diseases | 1 | 2015 | 76 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 159 | 0.110 |
Why?
|
| Linkage Disequilibrium | 3 | 2021 | 484 | 0.110 |
Why?
|
| Ovariectomy | 1 | 2014 | 98 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 102 | 0.100 |
Why?
|
| Mucin-1 | 1 | 2014 | 46 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2016 | 318 | 0.100 |
Why?
|
| Estrone | 1 | 2013 | 10 | 0.100 |
Why?
|
| G2 Phase | 1 | 2013 | 32 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 446 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 420 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2019 | 1529 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 320 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 513 | 0.090 |
Why?
|
| Infant | 3 | 2020 | 3361 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2016 | 670 | 0.090 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2014 | 147 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2020 | 1721 | 0.090 |
Why?
|
| Cell Division | 1 | 2013 | 690 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 1088 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 356 | 0.090 |
Why?
|
| DNA Mutational Analysis | 4 | 2016 | 554 | 0.080 |
Why?
|
| Micrognathism | 1 | 2010 | 11 | 0.080 |
Why?
|
| Eye Abnormalities | 1 | 2010 | 41 | 0.080 |
Why?
|
| Karyotyping | 1 | 2010 | 220 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2010 | 218 | 0.070 |
Why?
|
| Gene Duplication | 1 | 2010 | 130 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2022 | 420 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 369 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 1214 | 0.070 |
Why?
|
| Chicago | 1 | 2013 | 1519 | 0.070 |
Why?
|
| Developmental Disabilities | 1 | 2010 | 217 | 0.070 |
Why?
|
| Gene Expression | 3 | 2016 | 1322 | 0.070 |
Why?
|
| Family | 2 | 2020 | 329 | 0.060 |
Why?
|
| Genome, Human | 1 | 2012 | 834 | 0.060 |
Why?
|
| Peer Review | 1 | 2006 | 20 | 0.060 |
Why?
|
| Population Surveillance | 2 | 2019 | 219 | 0.060 |
Why?
|
| Lipoprotein(a) | 1 | 2026 | 33 | 0.060 |
Why?
|
| Accreditation | 1 | 2006 | 77 | 0.060 |
Why?
|
| Facies | 1 | 2025 | 34 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2025 | 4042 | 0.060 |
Why?
|
| Documentation | 1 | 2006 | 112 | 0.060 |
Why?
|
| Growth Disorders | 1 | 2025 | 65 | 0.060 |
Why?
|
| Homozygote | 2 | 2023 | 213 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 228 | 0.050 |
Why?
|
| Risk | 2 | 2016 | 660 | 0.050 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2014 | 4 | 0.050 |
Why?
|
| Radiation Oncology | 1 | 2006 | 130 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2006 | 250 | 0.050 |
Why?
|
| Protein Binding | 2 | 2020 | 1561 | 0.050 |
Why?
|
| Hospital Rapid Response Team | 1 | 2014 | 29 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2024 | 239 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2016 | 726 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2026 | 259 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2014 | 141 | 0.050 |
Why?
|
| United States | 4 | 2024 | 8262 | 0.050 |
Why?
|
| Factor V | 1 | 2023 | 9 | 0.050 |
Why?
|
| Prothrombin | 1 | 2023 | 19 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2070 | 0.050 |
Why?
|
| Apolipoprotein E4 | 1 | 2023 | 34 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 980 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 135 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1568 | 0.050 |
Why?
|
| Virulence | 1 | 2023 | 280 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2023 | 139 | 0.040 |
Why?
|
| Computational Biology | 2 | 2016 | 618 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 195 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2022 | 81 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 917 | 0.040 |
Why?
|
| Bernard-Soulier Syndrome | 1 | 2000 | 1 | 0.040 |
Why?
|
| Gallbladder Neoplasms | 1 | 2020 | 24 | 0.040 |
Why?
|
| Biopsy | 2 | 2015 | 1225 | 0.040 |
Why?
|
| Amphibian Proteins | 1 | 2020 | 4 | 0.040 |
Why?
|
| Calibration | 1 | 2020 | 109 | 0.040 |
Why?
|
| Morpholinos | 1 | 2020 | 13 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2014 | 602 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1974 | 0.040 |
Why?
|
| Xenopus | 1 | 2020 | 120 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1397 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1570 | 0.040 |
Why?
|
| Glycine | 1 | 2020 | 96 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2020 | 208 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2020 | 136 | 0.040 |
Why?
|
| Larva | 1 | 2020 | 139 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 71 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 2085 | 0.040 |
Why?
|
| Cell Line | 2 | 2015 | 2483 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 229 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 335 | 0.040 |
Why?
|
| Estrogens | 1 | 2020 | 202 | 0.040 |
Why?
|
| Retinitis Pigmentosa | 1 | 2019 | 37 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 78 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 171 | 0.040 |
Why?
|
| Menopause | 1 | 2019 | 95 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 262 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2020 | 716 | 0.030 |
Why?
|
| Mice | 3 | 2020 | 12735 | 0.030 |
Why?
|
| Child | 2 | 2020 | 7750 | 0.030 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 14 | 0.030 |
Why?
|
| Disclosure | 1 | 2018 | 98 | 0.030 |
Why?
|
| Pregnancy-Specific beta 1-Glycoproteins | 1 | 2017 | 1 | 0.030 |
Why?
|
| Transcription Factors, TFII | 1 | 2017 | 2 | 0.030 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 7 | 0.030 |
Why?
|
| Geography | 1 | 2018 | 249 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 3612 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 86 | 0.030 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 218 | 0.030 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2017 | 45 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2016 | 106 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 22 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 244 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 85 | 0.030 |
Why?
|
| RNA Splice Sites | 1 | 2016 | 60 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1787 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 469 | 0.030 |
Why?
|
| Public Health | 1 | 2017 | 161 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 108 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 73 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 553 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 2212 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 425 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 353 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 93 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2016 | 613 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 676 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 400 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2792 | 0.030 |
Why?
|
| Lysine | 1 | 2015 | 170 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2016 | 163 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 357 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 226 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2019 | 9770 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 657 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2019 | 487 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 369 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 299 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 583 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 28981 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 125 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 2224 | 0.020 |
Why?
|
| Skin | 1 | 2015 | 591 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2008 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 686 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1276 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 2897 | 0.020 |
Why?
|
| Data Collection | 1 | 2012 | 375 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 1145 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 2050 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2013 | 766 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 722 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 448 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1615 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1785 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 384 | 0.020 |
Why?
|
| Kidney | 1 | 2014 | 1121 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 1128 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 556 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1899 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 4044 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 1539 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 2896 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 5577 | 0.010 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2000 | 7 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2000 | 63 | 0.010 |
Why?
|
| Africa | 1 | 2000 | 113 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2000 | 110 | 0.010 |
Why?
|
| Family Health | 1 | 2000 | 157 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2000 | 150 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2000 | 832 | 0.010 |
Why?
|